PT  - JOURNAL ARTICLE
AU  - Hansen, Henrik
AU  - Bieler, Theresa
AU  - Beyer, Nina
AU  - Frølich, Anne
AU  - Kallemose, Thomas
AU  - Godtfedsen, Nina
TI  - How does EQ-5D-3L and HADS questionnaires perform in patients with COPD?
AID  - 10.1183/13993003.congress-2020.2461
DP  - 2020 Sep 07
TA  - European Respiratory Journal
PG  - 2461
VI  - 56
IP  - suppl 64
4099  - http://erj.ersjournals.com/content/56/suppl_64/2461.short
4100  - http://erj.ersjournals.com/content/56/suppl_64/2461.full
SO  - Eur Respir J2020 Sep 07; 56
AB  - Introduction: EQ-5D-3L and HADS are widely used questionnaires for respectively evaluating health related quality of life and anxiety-depressions symptoms and measuring effects from PR. Their performance in COPD patients has been sparsely investigated for their reliability and agreement errors.Aim: To investigate the inter-day test-retest reproducibility of the EQ-5D-3L and HADS in patients with COPD (GOLD III-IV).Methods: Patients recruited from an RCT completed the EQ-5D-3L (VAS and Utility) and HADS (Subscales: anxiety and depression) twice 10 days apart prior to intervention start.Results: 50 patients (22 females, mean [SD] age 67 [9] yrs.; FEV1 32[9] %; 6MWD 347 [102] meters; CAT 21 [6] points; BMI: 26 [6] kg/m2) completed the questionnaires. The inter-day test-retest reliability ICC was 0.87 (LL95CI: 0.76) and 0.77 (LL95CI: 0.59) for EQ-5D-VAS and utility, respectively; and 0.86 (LL95CI: 0.75) and 0.90 (LL95CI: 0.82) for HADS-anxiety and depression. The corresponding agreements (standard error of the measurement, SEM) were 6.8 (mmVAS); 0.1 (utility); 1.3 (anxiety-point) and 0.9 (depression point) respectively. Absolute inter-day test-retest differences were 1.1mmVAS (95%CI: -2.7; 4.8), -0.02 utility (95%CI: -0.04; 0.05), -0.1 anxiety-point (95%CI: -0.6; 0.8) and -0.2 depression-point (95%CI: -0.8; 0.2). Ceiling/flooring effect occurred in <5% of the scores.Conclusion: Both the EQ-5D-3L and HADS questionnaire demonstrated good to excellent inter-day test-retest reproducibility in patients with COPD (GOLD III-IV) and the SEM was small and below the established minimal clinical important difference indicating that the questionnaires are suitable to evaluate changes in patients with COPD.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2461.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).